Projectional radiography

Oxford Tech Company Adaptix Submits US Regulatory Clearance for Transformational Diagnostic Product

Retrieved on: 
Tuesday, July 12, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Technology, Radiation protection, Primary care, Tissue, DT, Scan (company), 3D, Tomosynthesis, MRI, Travel, CT, Patient, CEO, Next (2020 TV series), High-dependency unit, Radiology, Pedigree, Food, Apple Thunderbolt Display, Diagnosis, Time, Standard of care, Projectional radiography, Mark (given name), FPS, Medical imaging

OXFORD, England, July 12, 2022 /PRNewswire/ -- Medical imaging technology company Adaptix Limited (Adaptix) has submitted a 510(k) application to the U.S. Food and Drug Administration for its first medical imaging product ("NeXt 3D-Ortho"), allowing the company to begin marketing its Point-of-Care 3D orthopedic system in the United States.

Key Points: 
  • Adaptix, based at Oxford University Science Park, has developed novel technologies that allow affordable, low-dose 3D imaging at the Point-of-Care using Digital Tomosynthesis (DT), to provider quicker, more accurate diagnosis possibilities.
  • 2D X-ray is currently the world's dominant diagnostic modality, but frequently results in inconclusive reads due to areas of clinical interest being obscured by overlying and underlying tissues.
  • CT provides a more sensitive 3D image but at a far greater cost in terms of money, time and radiation dosage to the patient.
  • Mark Evans, Adaptix's CEO, stated, "This is the first of many innovations that Adaptix is excited about bringing to medical markets.

Oxford Tech Company Adaptix Submits US Regulatory Clearance for Transformational Diagnostic Product

Retrieved on: 
Tuesday, July 12, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Technology, Radiation protection, Primary care, Tissue, DT, Scan (company), 3D, Tomosynthesis, MRI, Travel, CT, Patient, CEO, Next (2020 TV series), High-dependency unit, Radiology, Pedigree, Food, Apple Thunderbolt Display, Diagnosis, Time, Standard of care, Projectional radiography, Mark (given name), FPS, Medical imaging

OXFORD, England, July 12, 2022 /PRNewswire/ -- Medical imaging technology company Adaptix Limited (Adaptix) has submitted a 510(k) application to the U.S. Food and Drug Administration for its first medical imaging product ("NeXt 3D-Ortho"), allowing the company to begin marketing its Point-of-Care 3D orthopedic system in the United States.

Key Points: 
  • Adaptix, based at Oxford University Science Park, has developed novel technologies that allow affordable, low-dose 3D imaging at the Point-of-Care using Digital Tomosynthesis (DT), to provider quicker, more accurate diagnosis possibilities.
  • 2D X-ray is currently the world's dominant diagnostic modality, but frequently results in inconclusive reads due to areas of clinical interest being obscured by overlying and underlying tissues.
  • CT provides a more sensitive 3D image but at a far greater cost in terms of money, time and radiation dosage to the patient.
  • Mark Evans, Adaptix's CEO, stated, "This is the first of many innovations that Adaptix is excited about bringing to medical markets.

AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, Health, Oncology, Medical devices, Angiography, Projectional radiography, Genuity

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 41st Annual Canaccord Genuity Virtual Growth Conference at 9:00 a.m.

Key Points: 
  • AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 41st Annual Canaccord Genuity Virtual Growth Conference at 9:00 a.m.
  • A live webcast of the presentation will be accessible through the Investors section of the Companys website at www.angiodynamics.com and will be available for replay following the event.
  • AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology.
  • AngioDynamics diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products, and venous products.

Volpara Health Receives FDA Clearance for Next-Generation Breast Density Algorithm and Architecture

Retrieved on: 
Thursday, July 29, 2021
Breast imaging, Clinical medicine, Medicine, Cancer screening, Mammography, Projectional radiography, Non-contact thermography, Breast cancer, Volpara

SEATTLE, July 29, 2021 /PRNewswire/ --Volpara Health,aglobal health technology software leader providing an integrated breast care platform for the delivery of personalizedbreast care, has received FDA clearance for the latest version of its key science algorithm, Volpara Imaging Software (VIS 3.2).

Key Points: 
  • SEATTLE, July 29, 2021 /PRNewswire/ --Volpara Health,aglobal health technology software leader providing an integrated breast care platform for the delivery of personalizedbreast care, has received FDA clearance for the latest version of its key science algorithm, Volpara Imaging Software (VIS 3.2).
  • VIS 3.2 improves the overall robustness of Volpara's industry-leading breast density assessment algorithm, incorporating learnings from artificial intelligence (AI).
  • Since receiving initial FDA clearance for Volpara Imaging Software in 2010, Volpara has now received four additional clearances for the key science algorithm behind its integrated Volpara Breast Health Platforma product suite designed to enable earlier detection of breast cancers through improved mammography quality and workflow, volumetric assessment of breast density, and personalized breast care.
  • The Volpara Breast Health Platform is supported by numerous patents, trademarks, and regulatory registrations, including FDA clearance and CE marking, and is validated by a volume of peer-reviewed publications unrivaled in the breast health industry.

Global Computed Tomography Market (2020 to 2025) - Featuring Canon, GE Healthcare and Siemens Healthineers Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, July 23, 2021
Medical devices, Health, X-ray computed tomography, Medicine, Clinical medicine, Radiology, Health care, Projectional radiography, Medical imaging, CT scan, Multidimensional signal processing, Computed tomography angiography, Angiography, Pulmonary embolism

An estimated 375 million computed tomography (CT) procedures are carried out globally, increasing annually by 3%-4%.

Key Points: 
  • An estimated 375 million computed tomography (CT) procedures are carried out globally, increasing annually by 3%-4%.
  • CT has become an indispensable tool in illness diagnosis and management, playing an instrumental role in COVID-19 management.
  • The dynamic CT industry involves many participants introducing technological innovations frequently to match the rapidly evolving needs of clinicians, radiologists, and technologists.
  • Coronary CT angiography is the most commonly used imaging modality to diagnose pulmonary embolism and will remain so during the forecast period.

Global Coronary Angiography Catheters and Guidewires Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Health, Cardiology, Angiography, Projectional radiography, Coronary catheterization

The "Global Coronary Angiography Catheters and Guidewires Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coronary Angiography Catheters and Guidewires Market" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the latest market data for the Global Coronary Angiography Catheters and Guidewires Market.
  • This report covers the impact of COVID-19 on the coronary angiography catheters and guidewires market, including a recent forecast from 2020 to 2025.
  • The report provides insights into trends, drivers, and limiters of the coronary angiography catheters and guidewires market, as well as highlights potential opportunities.

RamSoft Acquires a Majority Stake in Meddiff to Advance Patient Care Globally

Retrieved on: 
Tuesday, July 6, 2021
Medical imaging, Medicine, Medical physics, Breast imaging, Cancer screening, Mammography, Projectional radiography, Workflow, Radiology, Clinical medicine, Medical tests

RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.

Key Points: 
  • RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.
  • "Our commitment to saving patient lives through universal access to imaging is what drives us as a company.
  • To expand its global footprint and support this mission, RamSoftlooked towards Meddiff, a Bangalore-based company that has over 1,500 installed sites globally.
  • Built using cutting-edge, single database technology, our radiology, mammography, and enterprise imaging software enables practices tooptimize their workflow, cut costs, and overall, improve patient care.

RamSoft Acquires a Majority Stake in Meddiff to Advance Patient Care Globally

Retrieved on: 
Tuesday, July 6, 2021
Medical imaging, Medicine, Medical physics, Breast imaging, Cancer screening, Mammography, Projectional radiography, Workflow, Radiology, Clinical medicine, Medical tests

RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.

Key Points: 
  • RamSoft will continue to be headquartered in Toronto, Canada and the company's management team will be led by President and CEO Vijay Ramanathan.
  • "Our commitment to saving patient lives through universal access to imaging is what drives us as a company.
  • To expand its global footprint and support this mission, RamSoftlooked towards Meddiff, a Bangalore-based company that has over 1,500 installed sites globally.
  • Built using cutting-edge, single database technology, our radiology, mammography, and enterprise imaging software enables practices tooptimize their workflow, cut costs, and overall, improve patient care.

A1 Medical Imaging Commends Recent Research Confirming MRI Effectiveness in Detecting Early Recurrent Breast Cancer

Retrieved on: 
Wednesday, June 16, 2021
Medicine, Clinical medicine, Breast imaging, Medical physics, Cancer screening, Health, Medical imaging, Mammography, Projectional radiography, Breast cancer, Breast MRI, Magnetic resonance imaging

The research that was published June 8, 2021, in the Radiology journal concluded that breast MRI has been shown to improve the early detection of recurrent breast cancers that may be missed by mammography.

Key Points: 
  • The research that was published June 8, 2021, in the Radiology journal concluded that breast MRI has been shown to improve the early detection of recurrent breast cancers that may be missed by mammography.
  • Peter Solodko, A1 Medical Imaging's Chief Executive Officer, commented, "This research indicates that breast MRIs can detect early stages of cancer better than mammography in women with a past history of breast cancer."
  • A1 Medical Imaging has open MRI centers throughout Florida and in Georgiaand provides breast MRI screenings at its Aventura, Pembroke Pines, Plantation and Orange Park locations in Florida.
  • A1 Medical Imaging has become a model of excellence in the medical diagnostic imaging industry.

Global Mammography Systems Market (2021 to 2029) - Featuring Hologic, Phillips Healthcare and Toshiba Medical Systems Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 15, 2021
Health, Oncology, Medical devices, Clinical medicine, Medicine, Medical specialties, Biopsy, Cancer screening, Breast imaging, Mammography, Projectional radiography, Breast biopsy, Stereotactic surgery, Breast cancer, Planmed

Factors such as booming healthcare industry with developing healthcare infrastructure and rising investments, government initiatives and mounting awareness regarding regular monitoring and diagnosis are fuelling the global mammography systems market.

Key Points: 
  • Factors such as booming healthcare industry with developing healthcare infrastructure and rising investments, government initiatives and mounting awareness regarding regular monitoring and diagnosis are fuelling the global mammography systems market.
  • The products segment includes screen film mammography, digital mammography systems, analog mammography systems, stereotactic breast biopsy, and 3D mammography systems.
  • To assess the market competition, company profiling and market positioning of leading participants in the global mammography systems have been provided in the report.
  • Company profiling of major market players is done based on business overview, financial analysis, product portfolio and key recent developments of each company operating in the mammography systems market.